. . . . . . . "[The anti-leukemic activity of this RTM against BPL xenograft clones derived from CD22?E12(+) leukemia patients provides the preclinical proof-of-concept that correcting the CD22?E12 defect with rationally designed CD22 RTMs may provide the foundation for therapeutic innovations that are needed for successful treatment of high-risk and relapsed BPL patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:11:18+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .